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1 Introduction 
The development of resistance against anticancer drugs during chemotherapy is still 
a severe problem in the every-day oncology practice. Some tumor types are sensitive to 
the chemotherapeutic drugs in the beginning of treatment, but later on they become 
more and more resistant to the applied therapy, while other cancers are intrinsically 
resistant to numerous anticancer drugs they have never met before. Unfortunately, 
tumors can develop resistance against the majority of anticancer drugs that have 
different chemical nature and mechanism of action. This phenomenon was called 
multidrug resistance (MDR) and the causes and possible ways of its prevention or 
inhibition are intensively studied since the 1970’s. 
By the second half of the 1980’s it was proved, that the MDR phenotype of cancer 
cells is often related to the presence or increased expression of an active plasma 
membrane transporter called P-glycoprotein (Pgp). Based on the sequence of its cDNA, 
Pgp showed significant homology with certain bacterial transporters belonging to the 
ABC family of transport ATPases, and it became the first human member of the ABC 
protein superfamily.  
Afterwards 48 ABC protein genes were identified in the human genome and they 
were categorized into seven subfamilies (from ABCA to ABCG). The majority of them 
is active membrane transporters and thus, often called ABC transporters, while some of 
them are ion channels or ion channel regulators. However, the members of the ABCE 
and ABCF subfamilies are not transmembrane proteins. Similarly to Pgp many ABC 
transporters were proved to be involved in the development of the MDR phenotype, but 
the fist described Pgp remained the “prototype” of multidrug transporters. Therefore, 
Pgp is subject of a great scientific interest and its function and ways of inhibition are 
intensively studied.  
1.1 The structure and catalytic cycle of Pgp 
Pgp is the first member of the B subfamily of human ABC proteins encoded by the 
abcb1 (mdr1) gene that is located on chromosome 7. It is expressed in tissues of barrier 
functions (e.g. intestinal epithelium, capillary endothelial cells of the blood-brain 
barrier, hepatocytes), where it is presumably involved in the protection of our body 
against xenobiotics. Pgp is a 170 kDa glycoprotein composed of 1280 amino acids. It is 
a so-called “full transporter”, since one continuous polypeptide chain contains its two 
transmembrane domains (TMDs, each consisting six transmembrane α-helices) and two 
nucleotide binding domains (NBDs). The TMDs form the substrate binding site which 
is able to bind and export hundreds of compounds from the cell using the energy 
provided by ATP binding and hydrolysis carried out by the NBDs. The structure of the 
NBDs and the mechanism of ATP binding and hydrolysis is unique among ATP 
utilizing enzymes and transport ATPases. Although, the RecA-like structure of the 
NBDs containing the Walker A and Walker B sequences can be found in every 
ATPases, the ABC “signature” motifs are characteristic for the ABC proteins. Another 
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interesting feature of ABC proteins is the strong cooperation of the two NBDs upon 
ATP binding and hydrolysis. 
Despite accumulating significant amount of functional and structural data about 
human Pgp, there are no high resolution structures available that are based on x-ray 
crystallography data. Therefore, in molecule dynamic simulations homology models 
based on the crystal structures of bacterial ABC transporters or Pgps from mice or C. 
elegans are used. According to these studies two stabile conformers of Pgp can be 
assumed: in the absence of nucleotides, the NBD dimers are dissociated and the TMDs 
adopt an inward-facing conformation, which make the substrate binding site accessible 
from the intracellular space or from the inner leaflet of the membrane; while after ATP 
binding the two NBDs dimerize forming the outward-facing conformation which is 
closed towards the intracellular side of the membrane and open to the extracellular side. 
It is supposed that Pgp fluctuates between these two conformations.  
According to the general concept explaining the substrate transport by active 
transporters the substrate binding sites switch from high to low substrate affinity 
conformation to ensure transport against the concentration gradient. However, it is still 
unknown whether this affinity change is triggered by ATP hydrolysis or ATP binding 
itself. Also there is no consensus regarding the number of hydrolyzed ATPs per one 
catalytic cycle. 
To explore the catalytic cycle of Pgp, numerous biochemical experiments were 
carried out using mutant Pgp variants, in which certain key amino acids of the conserved 
sequences of one or both NBDs were exchanged. According to literature data, these 
mutations, depending on which conserved sequence is affected, stabilize the Pgp 
molecules at different stages of the catalytic cycle and abolish their ATPase activity 
regardless the mutation affected one or both NBDs. These experiments supported the 
idea, that the ATP hydrolysis activity of both NBDs is indispensable for Pgp function. 
This may imply that both catalytic sites should hydrolyze the bound ATP upon the 
catalytic cycle or alternatively only one ATP is hydrolyzed, but the two nucleotide 
binding sites should hydrolyze ATP in a strictly alternating manner. On the other hand 
the NBDs of Pgp molecules crystalized in the absence of substrate and ATP appears to 
be separated. If this conformation is indeed relevant and part of the catalytic cycle, it is 
possible that both ATPs are hydrolyzed during the cycle or alternatively after the 
hydrolysis of the first ATP the second one is unable to keep the NBD dimer together. 
Due to these contradictory results there is no consensus regarding the details of the 
catalytic cycle of Pgp in the scientific community. 
1.2 Clinical significance of Pgp 
Pgp is generally expressed in tissues having barrier functions and it is suggested to 
have an important role in the protection of the body from toxic substances. In the same 
time its expression in cancer cell causes multidrug resistance, hereby worsens the 
prognosis of many types of cancers and decreases the survival of patients. Early studies 
showed that loss of the abcb1a/b genes in mice (homologues of the human abcb1 gene) 
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is not accompanied by major physiological consequences. Thus, inhibition of Pgp 
molecules may be a plausible strategy for overcoming drug resistance without serious 
side effects. The classical pharmacological approach involves co-administration of 
cytotoxic compounds that are substrates of Pgp with pump inhibitors to increase the 
accumulation of the former one into the tumor cells. Unfortunately, upon clinical trials 
Pgp inhibitors induced unpredictable and intolerable pharmacokinetic interactions 
probably by inhibiting Pgp molecules expressed in barrier tissues leading to altered 
pharmacokinetics and increasing toxicity of the co-administered chemotherapeutic 
agents. 
In tumor patients many different resistance mechanisms can contribute to the 
development of the drug resistant phenotype; therefore their proper identification is 
crucial from the aspect of choosing the most suitable personalized therapy. On the other 
hand, it is important to expand the repertoire of therapeutic protocols that are able to 
overcome multidrug resistance. This also requires the establishment of appropriate 
models systems that can be used to test the new resistance reversal strategies in vivo. 
Several monoclonal antibodies (mAb) recognizing extracellular epitopes of Pgp 
have been developed. A few of them (e.g., MRK16, MRK17, MC57, HYB-241, and 
UIC2) are thought to recognize discontinuous conformation sensitive epitopes. Upon 
binding, these antibodies can partially inhibit Pgp mediated drug transport in vitro and 
in vivo. However, this inhibitory effect is often weak, its extent may depend on the 
transported substrate, and it is variable even in the case of the same substrate according 
to general experience. 
UIC2 is a monoclonal antibody that recognizes a complex conformation sensitive 
epitope on the extracellular part of Pgp. In the absence of Pgp substrates and modulators, 
UIC2 can bind only to 10–40% of cell surface Pgps, while the rest of Pgp molecules 
adopts the UIC2 binding conformation only in the presence of a distinct group of 
substrates or modulators (e.g., cyclosporine A (CsA), SDZ PSC 833, vinblastine and 
paclitaxel). In previous studies our workgroup has demonstrated that the UIC2 antibody 
itself completely inhibits Pgp function when it is applied together with any of the above 
Pgp modulators added at low, sub-inhibitory concentration that makes all cell surface 
Pgps UIC2 reactive. On the other hand, we also demonstrated in case of human tumors 
xenotransplanted into severe combined immunodeficient (SCID) mice that UIC2 could 
readily penetrate into the compact solid tumors, intensively staining cell surface Pgps 
and increasing daunorubicin accumulation in the Pgp+ tumors to the level of the Pgp- 
ones. 
These data rise the question whether the combined application of a class of 
modulators (including CsA) used at sub-inhibitory concentrations and of the UIC2 
antibody can increase the anti-tumor effect of cytostatic drugs (e.g. doxorubicin, 
daunorubicin) in Pgp expressing tumors and whether clinically relevant decrease in 
tumor mass can be achieved by the treatment.  
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2 Objectives 
Although the catalytic cycle of Pgp has been intensively studied for more than three 
decades, the connection between the different steps of the ATPase cycle and the 
rearrangement of the TMDs, which mediate the transport of the substrates against their 
concentration gradient, is still unclear. Considering the sensitivity of the ABC 
transporters to the composition of their membrane environment, opposed to previous 
studies applying heterologous expression systems or purified proteins, we decided to 
engineer mammalian cell lines expressing wild-type and mutant human Pgp variants at 
extremely high level and study them in their natural plasma membrane environment. 
Using this system we aimed to answer the following questions:    
 
• How does the substrate affinity of the Pgp change during the catalytic cycle? 
• How does the replacement of the conserved lysine amino acids of Walker A 
sequences in one or both NBDs to methionine (K433M and/or K1076M) affect the 
transport activity of the protein? 
• How do the above single and double Walker A mutations affect the transition of 
the protein between the high and low substrate affinity conformations? 
 
In previous studies our workgroup has demonstrated that binding of the UIC2 
antibody completely inhibits Pgp function when it is applied together with certain Pgp 
modulators, such as cyclosporine A (CsA) added at low, sub-inhibitory concentrations. 
In the present study we decided to generated and test an in vivo model system based on 
the xenotransplantation of Pgp+ and Pgp- tumors into SCID mice. Using this model 
system we aimed to answer the following questions:  
• Whether the combined treatment with CsA and UIC2 mAb can potentiate the 
anti-tumor effect of doxorubicin (DOX) in Pgp+ tumors to achieve clinically 
relevant reduction in tumor size?  
• Whether the partially functional immune system of the SCID mice can contribute 
to the observed antitumor effect of the combined treatment? 
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3 Materials and methods 
3.1 Ethics statement 
In animal experiments the Principles of Laboratory Animal Care (National Institute 
of Health) was strictly followed, and the experimental protocol was approved by the 
Laboratory Animal Care and Use Committee of the University of Debrecen (Permission 
Numbers: 26/2006/DE-MAB and 122/2009/DE-MAB). 
The human blood preparations (buffy coats) were obtained from the Debrecen 
Regional Center of Hungarian National Blood Transfusion Service and the blood 
plasma samples were donated by healthy volunteers. Written informed consent was 
obtained from donors prior to blood plasma donation, and their data were processed and 
stored according to the principles expressed in the Declaration of Helsinki. The 
experiments were done with the approval of the Scientific and Research Ethics 
Committee of the Medical Research Council (ETT TUKEB, permission number: 
25364-1/2012/EKU (449/P1/12.)). 
3.2 Cell lines 
In our experiments we used the NIH 3T3 mouse fibroblast cell line and its human 
mdr1 gene transfected variant  (NIH 3T3 MDR1); KB-3-1 human epidermoid 
carcinoma cell line and its Pgp+ subclone, KB-V-1; MDCK II (Madin-Darby canine 
kidney) cell line and its ABCG2 expressing variant; GLC4 human small cell lung 
carcinoma cell line and its MRP1 expressing variant. The mutant Pgp variant (K433M, 
K1076M and K433M/K1076M) expressing transgenic cell lines were made by our 
collaboration partners using Sleeping Beauty transposon based expression system and 
3T3 and MDCK cell lines. 
The cells were grown as adherent cultures at 37 °C in 5% CO2 atmosphere, in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with heat-inactivated 
fetal calf serum, L-glutamine and penicillin-streptomycin cocktail. The high expression 
of wild type Pgp was maintained by drug selection. Two days before the experiment, 
the cells were transferred into drug-free medium. Prior use, the cells were removed from 
the flask bottom by Trypsin-EDTA treatment.  
3.3 Direct immunofluorescence staining of Pgp  
To label cell surface Pgp molecules, the cell suspension was incubated for 30 
minutes at 37 °C with 15D3-A647 or with the combination of UIC2-A647 and 
cyclosporine A (CsA). Then the cells were washed three times with PBS containing 
glucose and FCS. The cells were analyzed by FACS Array or FACS Aria III flow 
cytometers. 
3.4 Indirect immunofluorescence staining of cell surface ABC transporters 
The cell suspension was incubated for 30 minutes at 37 °C with the appropriate 
primary antibody. Before labelling with QCLR-3 anti-MRP1 antibody, the cells were 
fixed and permeabilized, then incubated with the mAb for 30 minutes at 4 °C. Then the 
samples were washed three times and incubated for 30 minutes on ice with goat anti-
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mouse IgG, conjugated with CFL647. Following three washing, the cells were analyzed 
with FACS Aria III flow cytometer. 
3.5 Western blot analysis 
Proteins of the whole cell lysate (2.5 μg/sample) were subjected to SDS-
polyacrylamide gel electrophoresis on 8% polyacrylamide gel and electro-blotted to 
0.45 μm pore size nitrocellulose membrane. Pgp expression was detected by the G1 
anti-Pgp mAb and a goat anti-mouse HRP-conjugated IgG secondary antibody, both 
applied at 1:5,000 dilution. The ECL reaction was carried out with Super Signal West 
Femto ECL reagent and recorded using a Fluor Chem Q Alpha Innotech gel 
documentation system. 
3.6 Calcein and BODIPY-vinblastine accumulation tests 
The cells were pretreated with CsA, and then incubated with calcein acetoxymethyl 
ester or BODIPY FL-vinblastine (VBL-BPY) for 30 minutes. Following washes, the 
cells were kept on ice until the analysis. The dead cells were excluded from the analysis 
by propidium iodide (PI) staining. The transport activity of the Pgp was expressed as 
relative calcein accumulation increase, which is the fluorescence ratio of the CsA-
treated and untreated samples, both corrected with the background fluorescences.  
3.7 Rhodamine 123 efflux assay 
The cells were incubated with rhodamine 123 (R123, fluorescent Pgp substrate) for 
30 minutes. The samples containing wild type Pgp expressing cells also contained 
verapamil (competitive Pgp inhibitor). The excess R123 was removed by washing and 
the samples were kept on ice until the analysis. At the beginning of the measurement 
the cells were diluted with 37 °C R123 free medium and the fluorescence intensity of 
the cells were recorded continuously of 5 minutes using the temperature controlled 
sampling unit of the FACS Aria III flow cytometer. Later, after 10, 20, 30, 60 and 120 
minutes, the fluorescence of samples were also determined. The data were plotted on a 
time-fluorescence intensity graph, and the first order rate constant of the R123 efflux 
was determined by fitting an exponential curve on the data points. 
3.8 Labelling of intact cells with VBL-BPY and 15D3-A647 
The cells were cultured in 8 chamber Ibidi µ-Slide for two days, using an initial cell 
number to make a near confluent culture to the time of the experiment. Following three 
washes, the cells were pretreated with CsA or with the mixture of NaN3 and 2-deoxi-D-
glucose or Na2VO3 or N-ethylmaleimide (NEM) for 30 minutes at 37 °C. Then the 
samples were co-incubated with VBL-BPY and anti-Pgp mAb 15D3, conjugated with 
A647. At the end of the incubation the cells were washed three times, and then labelled 
with PI and images were taken using a confocal microscope. The PI positive, dead cells 
were excluded from the analysis. 
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3.9 Permeabilization of cells with Staphylococcus aureus α-toxin or 
streptolysin-O 
3T3 and MCDK cells were prepared in Ibidi µ-Slide IV0.4 slides for confocal 
microscopy, were permeabilized by Staphylococcus aureus α-toxin or streptolysin-O 
(SLO) respectively, with 30-60 minute incubation in the presence of DTT, protease 
inhibitor cocktail and FCS in HEPES buffer. The ratio of the permeabilized cells was 
determined by PI staining and we finished the permeabilization when at least the 80% 
of the cells become PI positive. Then the unbound toxins were removed by washing. 
3.10 Labelling of permeabilized cells with VBL-BPY and 15D3-A647 
After permeabilization the cells were washed three times, then preincubated for 30 
minutes with CsA or the mixture of ATP/MgCl2 and Na2VO3, or AMP-PNP/MgCl2 
followed by staining with VBL-BPY and 15D3-A647 for another 30 minutes. At the 
end of the incubation, the cells were washed three times, stained with PI and analyzed 
with confocal microscope. We used the permeabilized, PI positive cells for the analysis. 
3.11 In vitro cytotoxicity tests 
The KB-V1 and BK-3-1 cells were cultured in 96 well plates in drug-free medium 
for 24 hours, and then different concentrations of doxorubicin (DOX) were added to the 
appropriate wells together with CsA and/or UIC2 and incubated for further 72 hours. 
After it the medium was replaced with a fresh AlamarBlue containing one, and two 
hours later the reduced AlamarBlue content was determined by a microplate reader. The 
fluorescence intensities of the samples were proportional to the amount of the living 
cells in them. The ratios of the living cells were plotted against the concentration of the 
DOX, and after fitting of the dose-response curves, the half effective doses (EC50) of 
DOX were determined. 
3.12 In vitro antibody-dependent cell-mediated cytotoxicity (ADCC) assay 
Human peripheral blood mononuclear cells (PBMCs) were prepared from the blood 
of healthy donors by density gradient centrifugation. The PBMC rich fraction (effector 
cells) was washed two times and re-suspended in DMEM. KB-V1 and KB-3-1 (target 
cells) cells were labelled with 5(6)-carboxyfluorescein diacetate N-succinimidyl ester 
(CFDA-SE) for 10 minutes, then washed three times and re-suspended in DMEM. 
The target cells were mixed with effector cells at target/effector cell ratios of 1∶5, 
1∶10, 1∶50 and 1∶100, and then they were incubated in the presence or absence of CsA 
and/or UIC2 at 37 °C in CO2 incubator for 8 hours. After labelling with PI, the samples 
were analyzed by flow cytometer. The CFDA-SE+/PI+ subpopulation was considered as 
dead target cells, while CFDA-SE+/PI- ones were considered as living cells. The ratios 
of the CFDA-SE+/PI+ double positive cells to all CFDA-SE+ cells gave the ratio of the 
dead target cells, which were plotted against the target/effector cell ratios. 
3.13 In vitro complement-dependent cytotoxicity (CDC) assay 
Samples containing KB-V1 or KB-3-1 cells and UIC2 mAb in the presence or 
absence of CsA were treated with freshly prepared human serum at different dilutions. 
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The samples were incubated for 4 hours in CO2 incubator at 37°C then stained with PI 
and were analyzed by flow cytometer. The hemolytic activity of the applied human sera 
was determined using sheep red blood cells sensitized with rabbit stroma antibody. 
3.14 Animal experiments 
10 to 12 week-old, pathogen-free B-17 severe combined immunodeficiency (SCID) 
mice were used in this study. Animals were housed under pathogen free circumstances, 
the sterilized food and drinking water were available ad-libitum to all animals. 
SCID mice were injected subcutaneously with KB-3-1 and KB-V1 cells. To obtain 
approximately similar tumor sizes in case of KB-V1 and KB-3-1 cells we had to inject 
double number of KB-V1 cells, because of their slower cell proliferation rate. Tumors 
were grown for 4 days and then the mice were treated with DOX alone, or DOX 
combined with either UIC2 mAb or CsA or both. The animals were killed 8 days after 
treatment with chemotherapy by cervical dislocation and the tumors were removed to 
weigh them and then they were snap frozen in liquid nitrogen and stored till mRNA 
expression analysis. 
3.15 mRNA analysis 
The frozen tumor sections were equilibrated in 10 volumes pre-chilled RNAlater-
ICE solution at -20°C overnight to protect RNA from degradation and then total RNA 
was isolated. RNA was then subjected to reverse transcription-real time quantitative 
polymerase chain reaction (RT-qPCR) using the Taqman assay. Pgp mRNA expression 
was normalized to the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
expression. 
3.16 Confocal laser scanning microscopy 
Microscopy samples were analyzed by an Olympus FluoView 1000 confocal 
microscope equipped with an inverted IX-81 stand and an UPlanSApo 60× (NA=1,35) 
oil immersion objective. The 488-nm blue line of an argon-ion laser, and the 543-nm 
green and the 633-nm red helium-neon laser lines were used for the excitation of VBL-
BPY, PI and Alexa 647, respectively. Fluorescence intensities were detected in the 
spectral ranges of 500–530 nm, 555–655 nm and 655–755 nm, respectively. 
To assess the co-localization of VBL-BPY (green) and Alexa 647-conjugated 15D3 
(red) fluorescence signals, single optical slices of apical membrane surfaces were 
recorded for double-labelled cells, then the pattern and extent of co-localization in the 
sections were determined. The Pearson’s co-localization index (CI) provides a reliable 
estimate on the extent of fluorescence co-localization: CI values close to zero indicate 
no or a very low degree, while the CI = 1 value would correspond to a full overlap 
between the two colors in each pixel of the image, whereas -1 value means that the 
presence of a signal from one channel exclude the presence of the signal from the other. 
In case of permeabilized cells, due to the changes in the membrane structure we 
cannot acquire suitable images for CI calculation, therefore fluorescence intensity ratio 
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of VBL-BPY and 15D3-Alexa-647 was determined in pixels representing the plasma 
membrane selected on the basis of 15D3-Alexa-647 fluorescence intensity. 
3.17 Flow cytometry 
We used Becton Dickinson FACScan, FACS Array or FACS Aria III flow 
cytometers to measure whole cell fluorescence.  
In ADCC and CDC experiments a FACScan flow cytometer was used. Its 488 nm, 
blue laser was used to excite CFDA-SE and PI and the fluorescence intensities were 
detected through a 530/30 nm and 585/42 nm band-pass filters for CFDA-SE and PI, 
respectively. 
When FACS Array was used, PI was excited by the 532 nm diode laser, while A647 
was excited by the 633 nm laser, and the fluorescence intensities were detected through 
a 585/42 nm and 661/16 nm band-pass filters, respectively. 
Calcein, VBL-BPY accumulation and R123 efflux measurements were carried out 
on a Becton Dickinson FACSAria III Cell Sorter. Calcein, VBL-BPY and R123 were 
excited by the 488 nm line of a solid state laser and the emitted light was detected using 
a 502 nm dichroic mirror and a 530/30 nm band-pass filter. PI was excited by a 562 nm 
laser and the emitted light was detected applying a 590 nm dichroic mirror and a 
595/50 nm band-pass filter. Cell populations with high Pgp expression were sorted by 
FACS Aria III after direct immunofluorescence labelling with 15D3-A647. In this case 
the A647 dye was excited by a 633 nm laser and the fluorescence was detected through 
a 660/20 nm band-pass filter. 
3.18 Data and statistical analysis 
For image analysis ImageJ, Adobe Photoshop and Adobe Illustrator programs were 
used. Statistical analysis was carried out using SigmaStat or SPSS. Comparison of two 
groups was carried out by unpaired t-test, statistical significance in the case of three or 
more groups was assessed using analysis of variance (ANOVA), applying the Holm-
Sidak multiple comparison test for post hoc pair-wise comparison of the data. In the 
case of unequal variances Dunnett T3 post hoc pair-wise comparison method was used. 
Differences were considered significant at P < 0.05. 
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4 Results 
I. Examination of substrate binding of P-glycoprotein during the catalytic cycle 
4.1 MDCK cells can express wild type Pgp and its mutant variants at 
comparable level 
To compare the transport activity of the wild type and Walker A mutant Pgps, we 
needed cell lines that express the protein variants on similar levels. Therefore, we sorted 
the cell populations with homogenously high Pgp expression using 
immunofluorescence labelling followed by fluorescence activated cell sorting from the 
transgenic cell lines made by our collaboration partners. We checked the Pgp expression 
of the cell clones regularly by Western blot and flow cytometry. The expression level 
of the wild type and single mutant Pgp expressing cell lines did not differ significantly, 
while the double mutant Pgp expressing cells showed higher expression. 
4.2 Single Walker A mutant Pgps have residual transport activity 
We measured the transport activity of the Pgp variants by substrate accumulation 
tests, using calcein-AM. The transport activity of the Pgp variants was characterized by 
the CsA (cyclosporine A is a competitive Pgp inhibitor) sensitive calcein uptake. 
In the case of the wild type Pgp expressing cells the calcein accumulation of the CsA 
treated cells was 84.3±7.3 times higher compared to the untreated ones, which reflects 
the strong transport activity of the wild type Pgp. The relative calcein accumulation 
increase was much smaller in the case of the single mutant Pgps (12±0.8 fold and 
9.5±1.7 fold for the K433M and K1076M mutants, respectively), but still significantly 
higher than in the double mutant Pgp expressing cells (2.3±0.2 times) or the Pgp non-
expressing cells (1.4±0,3 times). Based on it we can assume that the single mutant Pgps 
have residual transport activity, while the mutation of both NBDs abolishes its transport 
function. 
To provide a quantitative measure of the residual transport activity of the single 
Walker A mutants, we determined the first order rate constants of rhodamine123 (R123) 
efflux from the cells. We loaded the cells with R123 and then transferred them into a 
larger volume of R123 free medium and measured the decrease of the R123 
fluorescence in the cells using flow cytometry.  
Our results showed that the rate constants in the case of the Pgp non expressing cells 
(0.02±0.01 min-1) and double Walker A mutant Pgp expressing cells (0.02±0.01 min-1) 
were identical and very low. In contrast with it, the values of the single Walker A mutant 
Pgp expressing cell lines were four times higher (0.1±0.02 min-1 and 0.09±0.01 min-1 in 
the case of K433M and K1076M cells, respectively), while the wild type Pgp expressing 
cells exhibited 30 times higher rate constant(0.7±0.06 min-1) compared to the Pgp non 
expressing cells. Taken together these data support the transport activity of single 
mutants, while the double mutant is inactive. 
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4.3 The single Walker A mutant Pgps are capable of conformational changes 
that alter reactivity with UIC2 mAb 
According to previous data of our workgroup, UIC2 mAb, when used alone, is able 
to bind to the 20-40% of the cell surface Pgps, but in the presence of CsA or as the result 
of ATP depletion all of them become UIC2 reactive. On the other hand, the presence of 
orthovanadate ion (Vi) reduces the fraction of the UIC2 recognizable Pgps. In our 
experiments we investigated whether the Walker A mutant Pgp variants are capable of 
the UIC2 detectable conformation changes. Single mutant Pgp expressing cells, 
similarly to the wild type expressing ones, showed increased UIC2 reactivity after CsA 
treatment or ATP depletion, while Vi, which stabilizes the post-hydrolysis transition 
state by replacing the phosphate ion in the NBD, caused significant decrease in UIC2 
reactivity. In contrast with it, double mutant Pgps showed high UIC2 mAb binding 
regardless of the treatments. Based on these results, we can conclude that the single 
mutant Pgps are capable of the switch between the UIC2 reactive and non-reactive 
conformations, while the double Walker A mutant Pgps are stabilized in the UIC2 
reactive conformation, and did not respond to the applied treatments. 
4.4 Modulators do not alter the amount of the cell surface Pgps 
Since most of the modulators used in our experiments may have a significant effect 
on the metabolism of cells, we checked whether they affect the cell surface expression 
of Pgps. Therefore, we pretreated the cells with the Pgp modulators and then labelled 
them with 15D3 mAb, which recognizes a conformation insensitive extracellular 
epitope of Pgp. Based on these experiments we concluded that the used modulators did 
not alter the cell surface Pgp expression level in the course of the labelling experiments. 
4.5 Single Walker A mutant Pgps are capable of switching between high and 
low substrate affinity conformations 
We demonstrated in substrate accumulation tests, that the BODIPY-FL conjugated 
variant of vinblastine (VBL-BPY), similarly to vinblastine, retained its Pgp substrate 
character. Investigating the cellular distribution of VBL-BPY we have found that it 
accumulated in intracellular vesicles in the Pgp- MDCK cells and no membrane staining 
could be observed. Consistently with the effective Pgp-mediated efflux of vinblastine-
bodipy (VBL-BPY), the cells expressing WT Pgp showed significantly lower levels of 
intracellular fluorescence as compared to the Pgp− cells ATP-depleted cells 
overexpressing wild-type Pgp showed increased intracellular fluorescence and more 
interestingly sequestered VBL-BPY in the plasma membrane as well. Strikingly, weak 
plasma membrane sequestration of VBL-BPY was also observed in cells transfected 
with single Walker A mutant Pgp variants, while double Walker A mutant Pgp 
expressing cells showed strong membrane staining. Addition of CsA, a competitive 
inhibitor of Pgp, prevented plasma membrane accumulation of VBL-BPY, suggesting 
that the enrichment of VBL-BPY in the plasma membrane is in each case due to its 
high-affinity binding to Pgp. 
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Since the signal of the VBL-BPY and the 15D3 mAb used to visualize Pgps 
correlated well, the fraction of the Pgps in substrate binding conformation could be 
determined by calculating the Pearson’s cross-correlation coefficients of the two 
signals. The antibody staining was unchanged in the course of the treatments supporting 
that the cross-correlation coefficients depend mostly on VBL-BPY binding to Pgp. In 
cells expressing double Walker A mutant Pgp large cross-correlation coefficients close 
to unity (~0.8) indicate that the majority of Pgp molecules are in high substrate affinity 
conformation. Competitive inhibitor (CsA) was able to prevent plasma membrane 
sequestration of VBL-BPY in all Pgp expressing cell lines, resulting in low cross 
correlation coefficients. Single Walker A mutants also exhibited somewhat increased 
drug binding compared to the WT, but this binding was fully suppressed by transition 
state analogs, e.g. vanadate. Furthermore, ATP depletion by Na-azide or prevention of 
ATP binding by NEM treatment shifted both single mutant and WT Pgp variants into 
the substrate binding conformation, as reflected by increased co-localization of VBL-
BPY and Pgp molecules in the plasma membrane. Remarkably, the high substrate 
affinity of double mutant Pgp was not affected by any of the above treatments. 
These results suggest that the single Walker A mutant Pgp variants are capable of 
switching between the high and low substrate affinity conformations, while the double 
mutant is stabilized in the high substrate affinity state. 
4.6 Nucleotide binding is sufficient to switch Pgp from high to low drug affinity 
conformation 
Since nucleotides are not membrane permeable, their effect on the conformation and 
substrate affinity of Pgp molecules cannot be studied in intact cells. Therefore, we 
permeabilized the NIH 3T3 MDR1 cells with Staphylococcus α-toxin and the MDCK 
cell lines with Streptolyzin-O, washed out the nucleotides, and then we co-incubated 
the cells with nucleotides and modulators followed by staining with VBL-BPY and 
15D3-A648 anti-Pgp mAb. Then the ratio of the VBL-BPY and 15D3-A648 
fluorescence was calculated in pixels representing the plasma membrane. Similarly to 
the previous experiments, the binding of 15D3-A647 was constant, the ratio of the 
fluorescence signals depended exclusively on the binding of VBL-BPY.  
In permeabilized cells ATP depletion synchronized WT Pgp molecules in a high 
drug binding affinity conformation, as indicated by VBL-BPY sequestration in the 
plasma membrane. This tight binding of VBL-BPY to Pgp was reversed in the presence 
of ATP and vanadate, consistent with the low drug binding affinity of the transition state 
complex. Strikingly, incubation of permeabilized cells with 5 mM AMP-PNP also 
resulted in a significant decrease in the co-localization of VBL-BPY and anti-Pgp mAb, 
indicating that the protein switched into a low substrate affinity concentration. Since 
AMP-PNP is a non-hydrolyzable ATP analogue, it can be assumed that ATP hydrolysis 
is not required for the decrease of the substrate affinity and the subsequent release of 
the substrate. 
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In the case of single Walker A mutant Pgp expressing cells the AMP-PNP caused 
smaller decrease in VBL-BPY binding compared to wild type Pgp expressing cells. In 
contrast, simultaneous mutation of both Walker A lysine residues 
resulted in a permanent high drug binding affinity conformation, which 
could not be reversed by the addition of nucleotides.  
4.7 Nucleotide binding reduces the UIC2 mAb reactivity of Pgp 
As it was presented in the previous section, the non-hydrolysable ATP analogue 
AMP-PNP stabilized the Pgp molecules in low substrate affinity conformation. We 
wanted to know whether this conformation change can be detected by UIC2 mAb. 
Removal of nucleotides synchronized Pgp molecules in the UIC2-reactive 
conformation, while addition of AMP-PNP reduced the UIC2 staining. Based on it we 
can conclude that AMP-PNP binding to the NBDs induces a conformation change in 
TMDs simultaneously decreasing the UIC2 reactivity and substrate affinity of Pgp. 
II. Investigation of inhibition mechanism of Pgp by UIC2 and its possible in vivo 
applications 
4.8 Experimental strategy 
To study the in vitro and in vivo effect of the combined application of UIC2, CsA 
and DOX, we used KB-3-1 human epidermoid carcinoma cell line and its vinblastine 
selected sub-clone, KB-V1. First, we wanted to know whether these cells are suitable 
for testing our Pgp inhibition strategy in vivo. Therefore, we determined the expression 
level of Pgp and other ABC transporters involved in the development of multidrug 
resistance (ABCG2 and ABCC1) in the KB cell line pair. The KB-3-1 and KB-V1 cells 
were injected subcutaneously into SCID mice, which were then treated with DOX, 
UIC2 and CsA or their combination on the fourth day of the experiment. Since palpable 
tumors were grown in the untreated mice by the twelfth day, we terminated the 
experiment, removed the tumors from the mice and determined their mass and 
compared their Pgp expression to that of the tumor cells used for grafting the tumors.  
4.9 KB-V1 cells express Pgp at high level 
Before we started in vivo experiments, we determined the cell surface expression 
level of the ABC transporters that are the most often responsible for the multidrug 
resistance (Pgp, ABCG2 and MRP1) in both cell lines. In the case of KB-3-1 no Pgp 
expression could be detected, while KB-V1 cells expressed Pgp at high level. Besides 
this neither ABCG2 nor ABCC1 (both has overlapping substrate spectrum with the Pgp) 
expression were detected in the cell lines. 
4.10 Pgp+ tumors retained their high Pgp expression level after 
xenotransplantation 
To design a model system that is suitable for testing our in vivo Pgp inhibition 
strategy, we had to verify that the transplanted cells retain their original Pgp expression 
level in the course of the experiment. Due to the high growth rate of KB cells, palpable 
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subcutaneous tumors developed in 10–12 days after their xenotransplantation. 
Therefore, the experiment was terminated on the twelfth day. The tumors were removed 
and heir Pgp mRNA level was determined by RT-qPCR and compared to those cells 
which were used for grafting the tumors. Pgp mRNA level of the KB-V1 tumors did not 
change upon proliferation of the inoculated cells, and it was at least three orders of 
magnitude higher than the Pgp mRNA level of the KB-3-1 cells. In the KB-3-1 tumors 
a well detectable ∼60-fold increment of Pgp mRNA levels occurred compared to the 
inoculated cells, but it was still negligible compared to the KB-V1 tumors. Thus, the 
KB-V1 tumor xenografts retained their MDR phenotype, while the KB-3-1 cells 
continued to express Pgp at very low levels in the developed tumors on the time scale 
of the in vivo experiments. 
Taken together the above model system can be suitable for testing our Pgp inhibition 
strategy in vivo. 
4.11 UIC2 mAb in combination with low dose of CsA could restore the 
doxorubicin sensitivity of the Pgp+ cells to the level of the Pgp- cells 
To test our Pgp inhibition strategy and the KB-3-1/KB-V1 cell lines, we performed 
in vitro cytotoxicity tests. In accordance with the high Pgp expression level of KB-V1 
cells were resistant to doxorubicin (DOX). The EC50 value of DOX was 2.19±0.39 µM 
in these cells, while it was only 44±3 nM in KB-3-1 (Pgp-) cells. In KB-V1 cells CsA 
co-treatment decreased the EC50 value of DOX in a dose dependent manner, while UIC2 
had only a weak, statistically not significant effect. Interestingly, the combined 
treatment of KB-V1 cells with 1 µM CsA and a saturating concentration of UIC2 mAb 
decreased the EC50 value to 33±19.7 nM, which was the sensitivity level of KB-3-1 
cells. Similar decrease could be achieved by 10 fold higher CsA concentration when it 
was applied alone.  
4.12 UIC2 mAb and CsA did not decrease the viability of KB cells neither used 
alone nor in combination 
We tested whether UIC2, CsA or their combination has any effect on the cells 
viability in vitro in the absence of DOX. Administration of the UIC2 mAb and 1 µM 
CsA to cultures of KB-3-1 cells, simultaneously or alone, had no significant effects on 
their DOX sensitivity. Therefore, in accordance with previous data of our workgroup, 
we can conclude that the treatment with the combination of CsA and UIC2 takes effect 
by reducing the KB-V1 cells DOX sensitivity. 
4.13 Combined treatment with DOX-CsA-UIC2 significantly decreased the 
growth rate of Pgp+ tumors 
 Based on the results discussed above, we designed in vivo experiments in which we 
investigated whether DOX in combination with low dose of CsA and UIC2 mAb is able 
to reduce the growth rate of the tumors in SCID mice that were developed from Pgp+ 
KB-V1 cells, which were injected subcutaneously into the animals. The animals were 
subjected to chemotherapy four days after the xenotransplantation, then eight days after 
chemotherapy, the animals were sacrificed by cervical dislocation and the tumors were 
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removed to weigh them. DOX treatment alone was almost ineffective in the case of KB-
V1 tumors, while the weight of the KB-3-1 tumors decreased considerably. Co-
administration of 10 mg/kg CsA decreased the size of the KB-V1 tumors only mildly 
and did not affect the KB-3-1 tumors. Combined treatment with DOX-CsA-UIC2 
decreased the mean weight of the KB-V1 tumors 9 fold compared to the animals treated 
with DOX alone. The combined treatment also decreased the mean weight of the KB-
3-1 tumors, but not in a statistically significant extent. Importantly, only 52% of the 
grafted Pgp+ or Pgp- tumors developed into detectable tumors in the DOX-CSA-UIC2 
treated animals, and 20% of the animals remained completely tumor-free. In contrast, 
we always detected tumors in the other treatment groups. Interestingly co-
administration of UIC2 and DOX also decreased tumor size significantly compared to 
DOX alone in the case of KB-V1 tumors. This finding, in view of the fact that UIC2 
treatment alone does not affect the EC50 value of DOX in in vitro cytotoxicity tests, 
suggested to us that the growth inhibitory effect of the antibody is not exclusively due 
to Pgp inhibition, therefore, the contribution of the immune system, that is partly 
functional in the SCID mice, was tested. 
4.14 UIC2 is able to trigger ADCC in vitro 
We tested whether UIC2 is able to induce antibody-dependent cell-mediated 
cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Since the 
experiments required a huge number of living immune cells, which could be obtained 
by sacrificing too many mice, we used human immune cells and serum instead. 
PBMCs killed about 70-80% of the UIC2 treated KB-V1 cells both in the presence 
and absence of CsA, at target to effector cell ratios of 1:50 and 1:100, respectively, in 
contrast with the UIC2 treated KB-3-1 cells that exhibited a survival rate similar to that 
of the untreated control. In the absence of UIC2, the percentages of dead target cells 
were low. In in vitro CDC experiments cell killing did not increase in the UIC2 treated 
KB-V1 and KB-3-1 samples despite the applied sera showed strong hemolytic activity 
in the control experiments. Based on these result we could assume that binding UIC2 to 
the Pgp+ cells induced ADCC but no CDC.  
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5 Discussion 
I. Examination of substrate binding ability of P-glycoprotein during the catalytic 
cycle 
Based on crystal structures and a wealth of biochemical and biophysical data it is 
generally accepted that ABC transporters have at least two discrete, energetically stabile 
conformations: one with dissociated NBDs that is opened toward the cytoplasm and 
another with dimerized NBDs and rearranged TMDs opened toward the extracellular 
space. The switch between the two states presumably involves a series of 
conformational changes which ultimately result in the reduction of substrate binding 
affinity required for uphill substrate transport. The exact molecular mechanisms that 
link nucleotide binding to the association and dissociation of NBDs and to the 
conformational changes of the TMDs that result in changes in substrate affinity are not 
fully understood. In the present study we correlated UIC2-reactivity with drug binding 
affinity for wild-type and mutant Pgp variants in permeabilized cells to elucidate the 
link between ATP binding, hydrolysis and the conformational rearrangements 
responsible for switching the affinity of the substrate binding sites during substrate 
transport. 
We used the UIC2 conformation sensitive mAb to detect molecular movements in 
the TMDs of the Pgp and we obtained information about the substrate affinity of the 
Pgp by measuring the co-localization between the fluorescence signals of VBL-BPY 
and 15D3-A647 at different stages of the catalytic cycle. In view of the intimate 
association of Pgp with the lipid bilayer in which it is embedded, and from which it 
harvests its substrates, the strength of our experimental systems that they provide 
information about the transporter in its natural plasma membrane environment. 
Our results demonstrated that AMP-PNP binding is sufficient to induce the 
conformational switch corresponding to the transition from the inward to the outward 
facing conformation that can be detected by UIC2 mAb. Using the same experimental 
setup, we also showed that binding of AMP-PNP switches Pgp into the low drug binding 
affinity state. The simultaneous drop in the UIC2- and drug-binding affinities suggests 
that the transition from the inward- to the outward-facing conformation precedes ATP 
hydrolysis in any case. 
Residues of the Walker motifs in each NBD, together with the signature sequence 
of the contralateral NBD, directly participate in nucleotide-dependent dimerization of 
the two NBDs and ATP hydrolysis. But how ATP hydrolysis is coordinated between 
the two NBDs, and whether Pgp hydrolyses one or two (or more) ATP molecules per 
each transported substrate are not known. Based on literature, mutations of the 
conserved Walker A lysine reduce ATPase activity to very low levels in diverse ABC 
transporters. The two nucleotide binding domains of Pgp were shown to be functionally 
equivalent and the integrity of both catalytic centers is generally believed to be needed 
for transport, because inactivation of a single NBD results in inhibition of ATPase and 
transport activities. 
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We confirmed that mutation of both Walker A lysine residues inactivates Pgp: as 
indicated by the lack of ATP-triggered conformational changes, the transporter is 
essentially frozen in the UIC2-reactive inward-open state characterized with high drug 
binding affinity. Intriguingly, however, our data showed that the inward-to-outward 
conformational switch can be triggered in the case of the single Walker A mutants 
together with the concomitant drop in drug binding affinity. Furthermore, we 
demonstrated that the stabile Pgp-ADP-vanadate complex forms similarly in the WT 
and the unilateral Walker A mutant Pgp variants, which is characterized by low 
substrate affinity and low UIC2-reactivity. Other observations of our workgroup also 
support the idea, that the single Walker A mutants have catalytic activity: they have a 
low, but measurable ATPase activity that can be stimulated by substrates and their 
expression confers mild drug resistance to the cells. Based on our drug transport 
experiments we can tell that the single Walker A mutants have a 10-15 percent 
“residual” transport activity compared to the wild type, which can only happen if they 
are  able to pass through the catalytic cycle repeatedly. 
While our experimental system has several limitations, we note that the majority of 
the studies reporting the inactivating effect of single Walker A mutations have been 
performed using heterologous expression systems such as Sf9, Saccharomyces 
cerevisiae or purified and reconstituted proteins. It is known that the plasma membrane 
composition influences the catalytic activity of ABC transporters, and the amount of 
membrane cholesterol influences Pgp activity. Since membrane cholesterol levels are 
significantly lower in lower eukaryotes, it may be that the low ATPase activity of the 
single Walker mutants was missed due to the different plasma membrane composition 
of the heterologous expression systems, or artefacts related to the solubilization, 
purification and reconstitution of the proteins. 
Our results are incompatible with catalytic cycle models supposing the hydrolysis 
of two ATPs per cycle. Similarly, our results are also difficult to reconcile with models 
suggesting that the two NBDs hydrolyze ATP in a strictly alternating order. If the NBDs 
were indeed recruited in a strictly alternating fashion, every second ATP would have to 
be processed by the mutant catalytic center, causing the cycle to stall. Instead, our results 
indicate that the wild-type catalytic site can hydrolyze ATP in repeated cycles without 
hydrolysis at the other NBD. The simplest interpretation of our data is that in WT Pgp 
one of the two functionally equivalent sites becomes committed to hydrolysis in each 
cycle on a random basis, whereas in the single mutants commitment of the only 
functional site initiates every cycle. 
II. Investigation of inhibition mechanism of Pgp by UIC2 and its possible in vivo 
applications 
Based on previous studies the UIC2 mAb can be used to inhibit Pgp mediated 
transport in vitro and in vivo. Similarly to other antibodies that exhibit conformation 
sensitive binding, UIC2 binds only to a small fraction of Pgps expressed in cell 
membrane. In the presence of certain modulators (e.g. CsA) applied at sub-inhibitory 
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concentrations all Pgp molecules become UIC2 reactive and therefore can be inhibited 
by the antibody. In our study we investigated whether the administration of UIC2 in 
combination with low-dose of modulator increases the effectivity of the chemotherapy. 
To investigate the effect of the combined therapy in vivo, we designed a model 
system based on the xenotransplantation of the KB-3-1/KB-V1 Pgp-/Pgp+ human 
epidermoid carcinoma cells lines into SCID mice. In the above model system, co-
treatment with UIC2 + CsA potentiated the anti-tumor effect of DOX and inhibited or 
hindered the development of KB-V1 Pgp+ tumors in vivo. At the same time, DOX 
treatment alone did not have a significant effect on the size of the KB-V1 tumors. These 
data are in line with the conclusions of our previously published in vitro and in vivo 
drug accumulation studies and with the results of the in vitro cytotoxicity 
measurements. However, in contrast with the in vitro cytotoxicity tests, in our in vivo 
experiments treatment with UIC2 alone also decreased the growth rate of the Pgp+ 
tumors These observations may suggest that the dramatic antitumor effect of the 
combined treatment is not the exclusive result of increased antibody binding with 
consequential Pgp inhibition and DOX accumulation, the mechanism is more complex. 
Therefore, the differences between the results of the in vitro cytotoxicity tests and in 
vivo experiments carried out on SCID mice raised the possibility that immunological 
processes could contribute to the cytotoxic effects of our treatment protocol. 
SCID mice, regardless their adaptive immune system is dysfunctional, have intact 
complement system as well as functioning macrophages, natural killer cells and 
polymorphonuclear cells. Therefore, antibody binding to the tumor cells may elicit 
cytotoxicity directly through complement binding (complement-dependent 
cytotoxicity, CDC) or indirectly, via the recruitment of the above effector cells to the 
antibody covered tumor cells (antibody-dependent cell-mediated cytotoxicity, ADCC). 
Our in vitro ADCC assays supported the notion that the UIC2 mAb induces ADCC in 
vivo in the SCID mice. 
The involvement of ADCC in the in vivo anti-tumor effect of UIC2 treatment is an 
unexpected finding of our experiments. IgG2 antibodies, which UIC2 belongs to, are 
mostly inefficient at supporting effector functions and are chosen for antibody therapy 
when effector functions are unnecessary or undesirable. Since IgG2 isotype antibodies 
do not trigger natural killer cell mediated ADCC, therefore in our in vitro ADCC 
experiments carried out with PBMCs cell killing was mediated by monocytes. Since 
SCID mice also have monocytes the same mechanism is functional and probably 
explains our in vivo results. 
The above results raise the question whether the strong anti-tumor effect of the 
combined treatment might be attributed exclusively to ADCC triggered by the UIC2 
mAb binding. However, the fact that the extents of the in vitro ADCC effects were 
indistinguishable in the presence of UIC2 or UIC2+CsA suggests that binding of the 
antibody to a small fraction of the cell surface Pgps (20-40%) is sufficient to induce a 
maximal ADCC effect. Consequently, the differences in the size of the KB-V1 tumors 
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between the UIC2 and UIC2+CsA treated animals and the lack of the KB-V1 tumors in 
52% of these animals argue against the above assumption and suggests that the stronger 
Pgp inhibitory effect of the UIC2+CsA combination mediates the anti-tumor effect at 
least in part. This hypothesis is supported by previous studies of our workgroup in which 
a two fold increase in the accumulation of a Pgp substrate daunorubicin (also a Pgp 
substrate cytostatic drug) was measured 8 hours after the injection of UIC2 and CsA 
added at similar conditions. Taken together, our in vitro and in vivo data suggest that 
strong anti-tumor effect can be reached by the combinative treatment studied, as a joint 
result of Pgp inhibition and ADCC.  
ADCC can be triggered at relatively low receptor occupancy by the antibody or at 
low receptor abundance. Thus, the 60 fold increased Pgp expression level of the KB-3-
1 tumors compared to the KB-3-1 cells is probably sufficient to trigger ADCC effect, 
when the Pgp molecules are saturated by the antibody in the presence of CsA. In line 
with this assumption in 52% of the DOX-UIC2-CsA treated animals we could not detect 
KB-3-1 tumors, while they appeared in all of the DOX or DOX+UIC2 treated animals. 
The Pgp specific nature of the observed effects was proved by our observation that 
decreased tumor size was detected exclusively in those animal groups that received 
UIC2 mAb treatment. In addition, in our previous studies we compared the KB-V1 cell 
line with mdr1 transfected NIH 3T3 murine fibroblast cells, and Pgp+ A2780AD ovarian 
carcinoma cells and found them equivalent in every aspect of their multidrug resistant 
phenotype including the inhibition of Pgp-mediated drug transport by UIC2 mAb. On 
the other hand, ADCC effect is not dependent on the tissue origin of the target cells; 
rather it is determined by the interaction between the Fc part of the antibody and the Fc 
receptor of the effector cells. 
Doubts about the possible clinical application of an anti-Pgp mAb based tumor 
therapy are related to the likely side effects that may arise as a result of either Pgp 
inhibition or ADCC, both exerted on cells expressing Pgp at physiological barriers of 
the body. For instance, inhibition of Pgp expressed in the blood-brain barrier may lead 
to increased accumulation of its substrates in the central nervous system leading to 
neurotoxicity (as it was experienced in mdr1a/b knock-out mice). However, 
administration of Pgp modulators in clinical trials does not seem to cause toxicity to the 
central nervous system probably because other ABC transporters (e.g. MRP1, BCRP1) 
may compensate for the loss of Pgp’s function. However, in contrast to Pgp inhibition, 
ADCC is more dangerous, because it may damage the tissues at the physiological Pgp 
expression sites. Since ADCC is mediated via the Fc portion of the antibody, to avoid 
this side-effect upon human applications the whole UIC2 antibody could be substituted 
for by its Fab fragments. Upon humanization of the antibody its effector functions may 
be also fine-tuned by the design of the Fc part. 
The UIC2 mAb does not bind to mouse Pgp, therefore the SCID mouse model 
system is not applicable for studying the possible side effects brought about by antibody 
binding to physiological Pgp expression sites. Since the UIC2 mAb also recognizes 
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primate and sheep Pgp, such animal models may be used for the evaluation of the 
feasibility of the strategy demonstrated herein. Direct injection of the antibody into the 
tumor tissue may also be tested for the purposes of reducing antibody dose and decrease 
systemic side effects. 
In our model system, treatments were applied shortly, four days after injection of 
the tumor cells, when the tumors were still rather small, the situation perhaps analogous 
to the clinical setting when systemic therapy is applied to prevent or hinder the 
development of multidrug resistant metastatic tumors. 
Each multidrug resistant tumor may have a unique signature of resistance 
mechanisms. Consequently, cancer therapy will need to be personalized, not only with 
respect to the mechanisms of malignant transformation or the tissue origin of the tumor 
but also regarding to the mechanisms of resistance. The strategy of Pgp inhibition 
demonstrated herein is offered to enrich the repertoire of possible protocols that can be 
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5.1 Summary 
 We have developed a fluorescence co-localization measurement based assay to 
detect the changes of the substrate affinity of Pgp upon distinct phases of its 
catalytic cycle. In addition, we adopted numerous fluorescence based techniques to 
measure the transport activity and conformation changes of Pgp. Using the 
mentioned assays we made the following statements regarding the catalytic 
mechanism of Pgp: 
 
• The conformation change of Pgp from the inward open, high substrate affinity 
state to the outward open, low substrate affinity conformation precedes the 
ATP hydrolysis. 
• The double Walker A mutant Pgp variant is catalytically inactive and trapped 
in the inward open, high substrate affinity conformation.  
• Single Walker A mutants have significant residual transport activity and thus 
they are capable of passing through full transport cycles, albeit with reduced 
efficiency. 
 
 We designed an in vivo model system based on the xenotransplantation of Pgp-
positive and Pgp-negative human tumors into SCID mice to test whether the 
combined treatment with low dose of CsA and UIC2 mAb can potentiate the anti-
tumor effect of doxorubicin.    
 
• Our results demonstrated that the combined treatment significantly increased 
the sensitivity of the Pgp expressing tumors to doxorubicin and decreased the 
growth rate of the tumors at a clinically relevant extent. 
• We also concluded that antibody-dependent cell-mediated cytotoxicity 
(ADCC) contributes to the anti-tumor effect of the combined treatment in vivo, 
besides Pgp inhibition.  
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